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ABSTRACT
Despite high protein expression and enzymatic activity of cytochrome P450 1B1 
(CYP1B1) in renal cell cancer (RCC), its functional significance has not been elucidated. 
Here we explored the functional role and regulatory mechanism of CYP1B1 in RCC. 
Reduction of CYP1B1 levels fail to prevent in vitro tumorigenicity such as proliferation, 
apoptosis, and cell cycle progression of RCC cells. Moreover, the expression levels are 
not associated with tumor type, stage, Fuhrman grade and 5-year survival probability 
after surgery. Instead, alteration of CYP1B1 expression regulates the chemosensitivity 
of RCC cells to docetaxel suggesting its critical contribution to the chemoresistance. 
Additionally, miR-200c, which is significantly down-regulated in RCC regulates CYP1B1 
expression and activity. An inverse association was also observed between the 
expression levels of miR-200c and CYP1B1 protein in RCC tissues. Finally, alteration 
of miR-200c levels affects the chemosensitivity of RCC cells. Restoration of docetaxel 
resistance by exogenous expression of CYP1B1 in miR-200c-over-expressing cells 
indicates that CYP1B1 is a functional target of miR-200c. These results suggest that 
CYP1B1 up-regulation mediated by low miR-200c is one of the mechanisms underlying 
resistance of RCC cells to docetaxel. Therefore, expression of CYP1B1 and miR-200c 
in RCC may be useful as a prediction for docetaxel response.
INTRODUCTION
Renal cell cancer (RCC) accounts for 2-3% of all 
tumor malignancies in human. In 2008, an estimated 
54,000 adults in the United States was diagnosed with 
RCC and approximately one third of newly diagnosed 
patients present with metastases [1]. The 5-year survival 
rate for patients with metastatic RCC is less than 
10% probably due to its low response to chemo- and 
radiotherapy [2]. 
Cytochrome P450 (CYP) is a multi-gene family of 
enzymes implicated in the metabolism of a diverse range 
of xenobiotics and endogenous compounds. Cytochrome 
P450 1B1 (CYP1B1) belongs to the CYP1 family 
and is the only member of the CYP1B subfamily. It is 
involved in the hydroxylation of estrogen and activation 
of environmental carcinogens [3]. CYP1B1 expression 
can be induced by polycyclic aromatic hydrocarbons 
such as 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin and is also 
regulated by peptide hormones, cAMP, aryl hydrocarbon 
receptor and estrogen receptor [4, 5]. CYP1B1 protein 
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is found in cancer cells but is undetectable in the normal 
cells of cancerous and normal tissues [6]. In contrast, 
there is no obvious difference in CYP1B1 mRNA levels 
between cancer and normal tissues, suggesting that its 
expression is regulated at the post-transcriptional level. 
Indeed, proteasome- and microRNA (miRNA)-mediated 
CYP1B1 regulation have been suggested to explain the 
discrepancy [7, 8]. The tumorigenic effects of CYP1B1 are 
believed to be its ability to produce 4-hydroxy estrogens 
via hydroxylation of the parent estrogen [9]. 4-Hydroxy-
estrogen undergoes further metabolic conversion to other 
reactive compounds such as estradiol-3, 4-quinone and 
semi-quinones. It has been postulated that DNA damage, 
mutation, and depurination caused by the metabolites 
of CYP1B1 activation initiate carcinogenesis [10]. 
In addition, CYP1B1 up-regulation is also thought to 
contribute to the chemoresistant phenotype of cancers. 
CYP1B1 overexpression decreased sensitivity to docetaxel 
in vitro [11] and its polymorphic allele leading both 
increased expression and activity is associated with poor 
response to taxanes in breast and prostate cancers [12, 13]. 
Due to these characteristics, CYP1B1 has been recognized 
as a potential tumor biomarker and a promising target 
for anticancer therapy. In fact, it has been demonstrated 
that CYP1B1 inhibition prevents endometrial and head 
and neck carcinogenesis [14, 15]. However, despite its 
potential tumorigenic effects, little is known about the 
functional significance of CYP1B1 in RCC.
MiRNAs are small noncoding RNAs of 
approximately 20-23 nucleotides that function in 
posttranscriptional gene regulatory pathways via targeting 
the 3’-untranslated region (UTR) of mRNAs [16]. 
Numerous studies have demonstrated that miRNAs have 
fundamental roles in many key cellular processes, such as 
proliferation, differentiation and apoptosis, and its altered 
expression has been described in many human cancers 
[17]. The miR-200 family containing miR-200a, -200b, 
-200c, -141 and -429 has been shown to play an important 
role in epithelial to mesenchymal transition (EMT) by 
repressing zinc finger E-box binding homeobox proteins 
1 and 2, and inducing E-cadherin expression [18]. Loss of 
miR-200 family members occurs in many different human 
cancers and miR-200c is down-regulated in RCC [19-21]. 
In addition to its role in EMT, miR-200c has been shown 
to regulate drug resistance of various types of cancers 
such as bladder [22], non-small cell lung [23], esophageal 
[24], breast [25], and ovarian [26] cancers. Although 
low response to chemotherapeutics is a distinctive 
characteristic of RCC, it is not known whether miR-200c 
is involved in RCC chemoresistance.
In this study, we show that CYP1B1 up-regulation, 
which is associated with the reduced miR-200c expression, 
is involved in the chemosensitivity of RCC cells to 
docetaxel. 
RESULTS
Functional role of CYP1B1 in RCC cells
To determine the functional significance of CYP1B1 
in RCC, we examined whether reduction of CYP1B1 
levels affects in vitro tumorigenicity. Transfection with 
two different CYP1B1 siRNAs resulted in a dramatic 
reduction in endogenous levels of CYP1B1 mRNA in 
A498 cells (Supplementary Fig. S1A). However, CYP1B1 
knockdown did not affect cell proliferation, apoptosis and 
cell cycle regulation (Supplementary Fig. S1B-D). Since 
the association of CYP1B1 with the docetaxel response 
has been studied both in vitro and in vivo [11-13], we 
examined the potential function of CYP1B1 in docetaxel 
resistance of RCC cells. According to the cytotoxic activity 
of docetaxel in several RCC cell lines, the resistance was 
found to be dependent on the cell line. Thus, A498 and 
Caki-2 cells exhibited high levels of resistance with IC50 
values of 74.6 and 66.8 µM, respectively, whereas ACHN 
and 786-O cells were significantly sensitive to docetaxel 
with IC50 values of 1.55 and 1.3 µM, respectively. Caki-
1 and 769-P cells showed a middle range of IC50 values 
of 11.0 and 24.0 µM, respectively (Fig. 1A). Next, we 
examined whether CYP1B1 expression is associated with 
the chemosensitivity to docetaxel. As shown in Fig. 1B 
and C, CYP1B1 protein levels in A498 and Caki-2 cells 
which present a resistant phenotype were relatively higher 
than that of ACHN and 786-O cells which were sensitive 
to docetaxel. In addition, after docetaxel treatment, 
ACHN and 786-O cells expressing relatively low levels 
of CYP1B1 protein exhibit reduced survival rate and 
less colony-forming ability than A498 and Caki-2 cells 
expressing relatively high levels of CYP1B1 protein 
(Fig. 1D and E). Flow cytometry analysis revealed a 
more significant increase in cell death of ACHN and 
786-O cells than A498 and Caki-2 cells (Fig. 1F). Since 
taxane-induced cytotoxicity is controlled by CYP2C8 
[27], CYP3A4 [28], and ABCB1 [29], we examined their 
protein expression in RCC cells. However, expression 
of these proteins was not correlated with the sensitivity 
to taxanes (data not shown). These results suggest that 
CYP1B1 may be involved in the regulation of RCC cell 
response to docetaxel.
CYP1B1 regulates RCC cell resistance docetaxel 
To determine whether the regulation of CYP1B1 
levels affects chemosensitivity to docetaxel, we performed 
knockdown experiments using CYP1B1 specific siRNA 
in A498 cells, which express relatively high levels of 
endogenous CYP1B1 protein. Transfection with two 
different CYP1B1 siRNAs results in a dramatic reduction 
in endogenous levels of CYP1B1 mRNA (Supplementary 
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Fig. S1A), protein (Fig. 2A) and enzyme activity (Fig. 2B). 
CYP1B1 knockdown significantly increased the cytotoxic 
effect of docetaxel (Fig. 2C) and decreased the survival 
rate of A498 cells (Fig. 2D). In reciprocal experiments, 
we examined whether CYP1B1 over-expression increased 
the chemoresistance of RCC cells to docetaxel. Transient 
transfection of a plasmid containing human CYP1B1 
into 786-O cells, which express relatively low levels of 
endogenous CYP1B1 protein resulted in a significant 
increase in protein level (Fig. 2E) and enzyme activity 
compared to transfection of control vector (Fig. 2F). 
Over-expression of CYP1B1 reduced the cytotoxic effect 
of docetaxel (Fig. 2G) and as a consequence, the survival 
of 786-O cells was also enhanced (Fig. 2H). Collectively, 
these results indicate that CYP1B1 plays an important role 
in the response of RCC cells to docetaxel.
Clinicopathologic analysis of CYP1B1 expression 
in RCC tissues
Despite high protein expression and elevated 
enzymatic activity of CYP1B1 in RCC [6, 30], the 
association of CYP1B1 with RCC development and 
clinicopathologic relevance is unknown. To determine 
whether the CYP1B1 protein expression levels are 
related with the clinicopathologic features and risk of 
RCC progression, we analyzed 59 patient samples who 
underwent nephrectomy for RCC, 24 of whom also had 
adjacent normal kidney samples available for analysis 
by immunohistochemistry. While the CYP1B1 level 
was weak or not detected in most of the normal tissues, 
majority of RCC tissue samples showed moderate or 
strong CYP1B1 immunoreactivity with average staining 
scores of 2.10 ± 0.11 (versus 0.60 ± 0.20 in normal tissues) 
(Fig. 3A and B). Unlike protein expression, no significant 
difference was observed in the levels of CYP1B1 mRNA 
in both RCC tissues and cell lines (Supplementary Fig. 
S2). According to the scoring, we categorized the RCC 
samples into weak (28.8%), moderate (32.2%) and strong 
(39.0%) staining groups (Fig. 3C). As shown in Fig. 3D, 
no correlation was observed between CYP1B1 levels and 
5-year survival probability after surgery (P = 0.8485). Of 
the RCC tissue samples, 49 of 59 (83%) were clear cell 
and 7 of 59 (11.9%) were papillary subtypes. In addition, 
3 of 59 (5.1%) tumors were identified as granular, tubular 
carcinoma, or oncocytoma (Table 1). We further assessed 
whether CYP1B1 expression in clinical samples are 
correlated with clinicopathologic characteristics such 
as tumor types, stage and Fuhrman grade. However, no 
statistically significant correlation was observed between 
Figure 1: CYP1B1 expression is involved in the docetaxel resistance of RCC cells. (A) Chemosensitivity assay was conducted 
at 72 h after docetaxel treatment. Values indicate mean IC50 ± SEM. (B) CYP1B1 protein expression in RCC cells was determined by 
Western blot. (C) The correlation of CYP1B1 protein expression with IC50. CYP1B1 protein level normalized by GAPDH expression was 
plotted against IC50 of different RCC cells. (D) Dose-dependent response of RCC cells was examined at 72 h after indicated concentration 
of docetaxel treatment. (E) Colony formation assay was performed at 14 days after docetaxel (5 µM) treatment. *P<0.05; ***P<0.001 (F) 
Cytotoxicity was measured with annexin V-FITC/7-AAD staining at 72 h after docetaxel (5 µM) treatment. *P<0.05; **P<0.01
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Figure 2: Change in CYP1B1 expression alters docetaxel resistance of RCC cells. (A and B) After siRNA transfection, 
CYP1B1 protein expression was determined by Western blot (A) and enzyme activity was measured with P450-Glo assay (B) in A498 cells. 
*P<0.05; **P<0.01 (C and D) After CYP1B1 siRNA transfection, A498 cells were treated with docetaxel (5 µM) for 72 hrs. Apoptotic 
cell death was measured with annexin V-FITC/7-AAD staining (C) and cell survival was analyzed by MTS assay (D). *P<0.05 (E and F) 
After plasmid transfection, CYP1B1 protein expression was determined by Western blot (E) and enzyme activity was measured with P450-
Glo assay (F) in 786-O cells. *P<0.05 (G and H) After CYP1B1 plasmid transfection, 786-O cells were treated with docetaxel (5 µM) for 
72 hrs. Apoptotic cell death was measured with annexin V-FITC/7-AAD staining (G) and cell survival was analyzed by MTS assay (H). 
*P<0.05; **P<0.01
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CYP1B1 expression and these pathological parameters. A 
comprehensive summary of the CYP1B1 staining patterns 
and its association with several clinicopathologic variables 
is shown in Table 1. 
CYP1B1 level is inversely correlated with miR-
200c expression in RCC
Since CYP1B1 overexpression causes resistance 
of RCC cells to docetaxel, we looked of the regulatory 
mechanisms of CYP1B1 expression with a focus on 
miRNAs. We searched for potential candidate miRNAs, 
which have been reported to be altered in RCC. According 
to miRNA expression profiling studies, miR-200c is 
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significantly down-regulated in RCC [19, 20]. Therefore, 
we analyzed miR-200c expression in microdissected 
human renal cancer tissues and matched adjacent normal 
regions, which were used for the CYP1B1 expression 
study (n = 24). While the expression of miR-200c was 
unaltered in 4 samples or up-regulated in 3 of the 24 cases, 
most of RCC tissues (17 of 24 cases) had low miR-200c 
levels relative to the matched normal samples (Fig. 4A 
and B). We verified these results by in situ hybridization 
analysis and again observed attenuated miR-200c 
expression (Fig. 4C). Patient and tumor characteristics 
used in these studies are summarized in Supplementary 
Table S1. 
To determine whether miR-200c expression is 
associated with CYP1B1 level, we investigated the 
relationship between the levels of CYP1B1 protein and 
miR-200c in human RCC tissues (Fig. 4D). RCC tumors 
with strong CYP1B1 expression showed low miR-
200c levels (1.87 ± 0.36 versus 5.14 ± 0.58 in tumor 
samples with weak CYP1B1 expression). In addition, 
a significant difference was also observed between 
RCC tumors with moderate and low CYP1B1 levels 
(3.36±0.50 versus 5.14±0.58 in tumor samples with 
weak CYP1B1 expression). Thus, an inverse association 
was found between miR-200c expression and CYP1B1 
protein levels in human RCC tissues. In addition to the 
majority of RCC cell lines showed low expression of miR-
200c compared with HK-2 cells but 786-O cells, which 
express low CYP1B1 levels exhibited high miR-200c 
expression (Fig. 4E). In contrast to the CYP1B1 protein 
level, no relationship was found between CYP1B1 mRNA 
and miR-200c expression in the human RCC tissues 
(Supplementary Fig. S3). These results suggest that low 
expression of miR-200c results in high levels of CYP1B1 
protein in RCC tumors.
CYP1B1 is a direct target of miR-200c 
In silico analysis (http://www.microrna.org/ and 
http://targetscan.org/) showed that CYP1B1 3’-UTR 
contains two potential complementary miR-200c binding 
sequences which are termed miR-200c complementary 
Figure 3: CYP1B1 protein is up-regulated in RCC tissues. (A) Immunohistochemical staining of CYP1B1 protein expression in 
RCC patients tissues. (a-d) Representative images showing immunoreactive CYP1B1 in normal (a) and RCC (b-d) tissues (magnification: 
×400). (B) Summary of CYP1B1 immunostaining score. Staining intensity was assessed as described in Materials and Methods. ***P<0.001 
(C) Summary of CYP1B1 expression levels in RCC tissue samples. (D) Kaplan-Meier analysis for the correlation of CYP1B1 expression 
with 5 year survival after surgery in RCC patients.
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sequence 1 and 2, respectively (MCS1 and MCS2) 
(Fig. 5A). To examine whether CYP1B1 expression is 
regulated by miR-200c, we cloned various 3’UTR reporter 
constructs containing the MCSs or controls (Fig. 5B) and 
conducted luciferase assays with 786-O and A498 cells, 
respectively. With 786-O cells, the luciferase activity of 
the construct containing two copies (pMir-1B1/MCS1-
MCS2) or one copy (pMir-1B1/MCS1 or pMir-1B1-
MCS2) of MCS was significantly lower than that of 
the control plasmid. However, the luciferase activity of 
the construct containing no MCS (pMir-1B1/∆MCS1-
∆MCS2) showed no change compared to the control 
vector. In A498 cells, only the luciferase activity of pMir-
1B1/MCS1-MCS2 was significantly decreased probably 
due to the low endogenous miR-200c expression. To 
investigate the direct regulation of CYP1B1 expression 
by miR-200c, luciferase activities were measured after 
miR-200c inhibition or overexpression. As shown in 
Fig. 5D, inhibition of endogenous miR-200c increased 
the luciferase activities of the pMir-1B1/MCS1-MCS2 
but not that of pMir-1B1/∆MCS1-∆MCS2. In reciprocal 
experiments, exogenous miR-200c expression decreased 
Figure 4: Inverse correlation between endogenous miR-200c level and CYP1B1 protein expression. (A) MiR-200c 
expression in RCC tissues. MiR-200c levels were analyzed by RT-PCR with RNA from microdissected tumor (T) and adjacent normal (N) 
tissues. (B) Summary of miR-200c expression levels in RCC tissue samples. (C) In situ hybridization of miR-200c expression in normal 
and RCC tissues. (D) Association of CYP1B1 expression with miR-200c levels in RCC tissues. MiR-200c levels were measured by RT-
PCR with RNA extracted from different scored and microdissected RCC tissue samples. *P<0.05; ***P<0.001 (E) Relative miR-200c 
expression in RCC cells was analyzed by RT-PCR. 
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Figure 5: MiR-200c directly targets the CYP1B1 3’-UTR. (A) Sequence and location of MCS1 and 2 in the 3’-UTR of human 
CYP1B1 mRNA. (B) Diagram of reporter constructs containing the wild type or MCS-deleted 3’-UTR of human CYP1B1. (C) Relative 
luciferase activity after transfection of reporter constructs containing the wild type or MCS-deleted 3’-UTR of CYP1B1. **P<0.01; 
***P<0.001; n.s.: non-significant (D) Relative luciferase activity after co-transfection of reporter constructs containing the wild type or 
MCS-deleted 3’-UTR of CYP1B1with either miR-200c inhibitor or precursor. *P<0.05; **P<0.01; n.s.: non-significant (E-G) After miR-
200c inhibitor transfection, relative miR-200c expression was analyzed by RT-PCR (E), CYP1B1 protein level was determined by Western 
blot (F) and enzyme activity was measured with P450-Glo assay (G) in 786-O cells. *P<0.05; ***P<0.001 (H-J) After miR-200c precursor 
transfection, relative miR-200c expression was analyzed by RT-PCR (H), CYP1B1 protein level was determined by Western blot (I) and 
enzyme activity was measured with P450-Glo assay (J) in A498 cells. **P<0.01
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the luciferase activities of the pMir-1B1/MCS1-MCS2 
but not that of pMir-1B1/∆MCS1-∆MCS2. These results 
suggest that miR-200c directly targets the MCS on the 
CYP1B1 3’-UTR and regulates its expression.
Next, we examined the effect of miR-200c on 
CYP1B1 protein levels and its enzymatic activity. In 786-
O cells, endogenous miR-200c levels were decreased by 
the miR-200c inhibitor (Fig. 5E). As shown in Fig. 5F and 
G, the CYP1B1 protein level and enzyme activity were 
significantly increased by the miR-200c inhibition. In 
reciprocal experiments, we also looked the effects of miR-
200c overexpression in A498 cells. MiR-200c expression 
was greatly increased by the transfection of its precursor 
in A498 cells (Fig. 5H). Conversely, CYP1B1 protein and 
enzyme activity were significantly decreased by miR-200c 
overexpression (Fig. 5I and J). These results suggest that 
miR-200c represses CYP1B1 mRNA expression resulting 
in the reduction of CYP1B1 protein level and enzymatic 
activity.
MiR-200c-mediated CYP1B1 regulation affects 
the resistance of RCC cells to docetaxel
To determine whether miR-200c affects RCC 
chemosensitivity, the cytotoxic effect of docetaxel was 
measured after miR-200c restoration or inhibition. A 
significant increase in the cytotoxic effect of docetaxel 
was observed and as a consequence, the cell survival 
rate was reduced by transfection of miR-200c precursor 
in A498 cells (Fig. 6A and B). MiR-200c inhibition 
significantly decreased the cytotoxic effect of docetaxel 
and enhanced the survival rate of 786-O cells (Fig. 6C 
and D). To verify the effects of miR-200c via CYP1B1 
on the chemosensitivity to docetaxel, we introduced 
CYP1B1 plasmid into A498 cells after miR-200c 
overexpression and examined cytotoxicity. Restoration 
of CYP1B1 protein levels was verified after transfection 
(Fig. 6E). We observed that the increase in the cytotoxic 
effect of docetaxel by miR-200c overexpression was 
reversed by the enforced CYP1B1 expression (Fig. 6F). 
As a consequence, cell survival was also restored by the 
exogenous CYP1B1expression (Fig. 6G). These results 
indicate that CYP1B1 regulation by miR-200c directly 
influences the chemosensitivity of RCC cells to docetaxel.
DISCUSSION
It has been suggested that CYP1B1 may be 
important in tumor development and progression, and 
also contributes to drug resistance [31, 32]. Saini et al. 
showed that CYP1B1 up-regulation plays an essential 
role in endometrial carcinogenesis [14]. In head and 
neck carcinogenesis, CYP1B1 knockdown reduced the 
migration and proliferation of premalignant cells [15]. 
Based on these studies, we examined the functional role 
of CYP1B1 in RCC using siRNA-mediated CYP1B1 
knockdown. Unlike other studies, CYP1B1 deficiency 
had no influence on RCC tumorigenicity. Interestingly, 
we found that CYP1B1 is involved in the docetaxel 
resistance of RCC cells. CYP1B1 overexpression in 
V79 cells reduced the in vitro cytotoxicity of docetaxel 
and this effect was reversed in the presence of CYP1B1 
inhibitor [11]. Although it is controversial [33, 34], one 
of the CYP1B1 polymorphic variants, Leu432Val, which 
may increase enzymatic activity, is associated with 
low response to taxane in breast cancer [12] and poor 
prognosis in docetaxel-treated prostate cancer patients 
[13, 35]. The L432V allelic variants were also associated 
with reduced sensitivity to DNA-interacting agents, 
alkylators, camptothecins, topoisomerase II inhibitors, 
and antimetabolites [36]. Our previous study suggests 
that CYP1B1 gene polymorphisms are risk factors for 
RCC [37]. Therefore, it would be of interest to determine 
whether the CYP1B1 polymorphic variants, especially the 
L432V allelic variant, are related to the resistance of RCC 
to chemotherapeutics. 
Several hypotheses have been proposed to 
explain how CYP1B1 decreases the cytotoxic effect 
of docetaxel. Rochat et al. initially suggested that 
docetaxel is metabolized by CYP1B1 [32]. However, 
other studies were unable to detect catalytic activity and 
effect of CYP1B1 during the metabolism and clearance 
of docetaxel, respectively [13, 38]. Sissung et al. showed 
that both 2-OHE2 and 4-OHE2, the catechol estrogen 
metabolites of CYP1B1 hamper the docetaxel-mediated 
tubulin polymerization. They also presumed that the 
covalent binding of CYP1B1-catalyzed E2-3, 4-quinone 
to docetaxel may reduce the cytotoxic potency of the 
drug [13]. CYP1B1 expression or its metabolites may 
also trigger an intracellular protective signaling pathway 
against docetaxel cytotoxicity. Martinez et al. showed that 
docetaxel induces CYP1B1 expression and drug resistance 
in breast but not in lung, colon, or pancreatic cancer cells. 
They also suggested that docetaxel resistance is not due to 
the direct inactivation of docetaxel by CYP1B1 but rather 
the indirect mechanism of promoting cancer cell survival 
based on the pro-apoptotic effect of CYP1B1 knockdown 
in endometrial cancer cells [39]. However, in RCC cells, 
CYP1B1 reduction does not affect tumorigenicity and 
no docetaxel-mediated CYP1B1induction was observed 
(Supplementary Fig. S1 and S4). Therefore, it may be 
possible that CYP1B1 is involved in docetaxel resistance 
through diverse mechanisms in each different type of 
cancer. MiR-200c is an important regulator of EMT, which 
has been suggested as one of the regulatory mechanisms 
of drug resistance [40]. According to our study, CYP1B1 
is an essential target of miR-200c-mediated docetaxel 
resistance. Thus, further studies are needed to determine 
whether CYP1B1 is involved in EMT.
CYP1B1 has been considered to be a promising 
prognostic and diagnostic marker for RCC, however 
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no studies have been conducted to document it so far. 
In this study, we examined the association between 
CYP1B1 expression and RCC clinicopathologic factors. 
However, no correlation was observed between CYP1B1 
expression and RCC tumor type, stage, grade, and 
5-year survival probability after surgery. Importantly, we 
observed that CYP1B1 expression is associated with the 
chemosensitivity of RCC cells to docetaxel. Although our 
sample number is small, it was enough to obtain statistical 
significance. A larger sample size might be needed to draw 
a more concrete conclusion about the association between 
CYP1B1 expression and clinical indicators of RCCs. 
In addition, it will be helpful to perform studies on the 
association of CYP1B1 expression and its polymorphic 
variants with the efficiency of docetaxel treatment in RCC 
patients to confirm this study.
Several reports have indicated that miR-200c is 
down-regulated in RCC tissues [19-21]. However, little 
is known about the functional significance of low miR-
200c expression in RCC. Reduced miR-200c level is 
associated with aggressiveness and chemoresistance in 
female reproductive cancers and its restoration enhances 
sensitivity to paclitaxel by targeting class III beta tubulin 
[41, 42]. In addition, miR-200c is associated with 
cisplatin and doxorubicin sensitivity through regulation 
of Akt, AP-2α, TrkB and Bmi1 [24, 25, 43]. In this 
Figure 6: MiR-200c regulates docetaxel resistance of RCC cells. (A and B) After miR-200c precursor transfection, A498 cells 
were treated with docetaxel (5 µM) for 72 hrs. Apoptotic cell death was measured with annexin V-FITC/7-AAD staining (A) and cell 
survival was analyzed by MTS assay (B). **P<0.01; ***P<0.001 (C and D) After miR-200c inhibitor transfection, 786-O cells were treated 
with docetaxel (5 µM) for 72 hrs. Apoptotic cell death was measured with annexin V-FITC/7-AAD staining (C) and cell survival was 
analyzed by MTS assay (D). *P<0.05; **P<0.01 (E-G) After transfection of miR-200c precursor with either control or CYP1B1 plasmid, 
A498 cells were treated with docetaxel (5 µM) for 72 hrs. CYP1B1 protein expression was determined by Western blot (E), apoptotic cell 
death was measured with annexin V-FITC/7-AAD staining (F) and cell survival was analyzed by MTS assay (G). *P<0.05; **P<0.01
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study, we identified CYP1B1 to be an effector for miR-
200c-mediated regulation of RCC chemosensitivity to 
docetaxel. Therefore, it would be of interest to examine 
whether genes known to be related with drug resistance 
such as ATP-binding cassette transporters and major 
vault protein are also regulated by miR-200c. According 
to Tsuchiya et al., lack of miR-27b which inhibits the 
translation of CYP1B1 mRNA into protein in normal but 
not cancer cells causes up-regulation of CYP1B1 protein 
level in breast cancer cells [7]. Therefore, it would be of 
great interest to determine whether miR-27b-mediated 
CYP1B1 regulation is involved in docetaxel resistance in 
both breast and kidney cancers. The information obtained 
by these types of studies will provide additional insight 
into understanding the significance of miRNAs in RCC 
drug resistance.
In conclusion, the present findings indicate that 
CYP1B1 is post-transcriptionally regulated by miR-
200c and thus, high CYP1B1 protein expression and 
enzyme activity may be caused by low expression of 
miR-200c in RCC. CYP1B1 up-regulation is not related 
to tumorigenicity and is unlikely to be associated with 
RCC clinicopathological parameters. Interestingly, our 
study found that miR-200c-mediated CYP1B1 regulation 
is involved in the chemosensitiviy of RCC to docetaxel. 
These results indicate that CYP1B1 and miR-200c may 
be useful as potential biomarkers for chemotherapy and 
therefore, help to provide more options for RCC treatment.
MATERIALS AND METHODS
Cell lines and reagents
The renal cancer cell lines, Caki-1, Caki-2, A498, 
ACHN, 786-O and 769-P were obtained from the 
American Type Culture Collection. McCoy’s 5A, MEM 
Eagle’s with Earle’s BSS (EMEM), RPMI 1640, Opti-
MEM and penicillin/streptomycin mixtures were obtained 
from the UCSF Cell Culture Facility. Fetal bovine serum 
(FBS) was a product of Atlanta Biologicals. Docetaxel 
was purchased from Sigma Chemical Co. 
Cell culture
Caki-1 and Caki-2 cells were grown in McCoy’s 5A, 
and A498 and ACHN cells were maintained in EMEM 
medium while 786-O and 769-P cells were cultured in 
RPMI 1640 medium. All culture medium contained 10% 
FBS and 100 µg/ml penicillin/streptomycin. All cell lines 
were maintained at 37°C in a humidified atmosphere 
composed of 5 % CO2 /95 % air.
Cell viability assay
For chemosensitivity assay, cells were seeded in 
triplicate in 96-well plates at a density of 250-1,000 cells/
well as appropriate and grown for 24h and then treated 
with docetaxel at 10 serially diluted concentrations 
between 0.05 and 100 µM for 72 h. For cell survival assay, 
cells were plated in triplicate in 96-well plates at a density 
of 5,000 cells/well and then treated with docetaxel. In some 
cases, miR-200c precursor, inhibitor, CYP1B1 plasmid or 
siRNAs along with their controls were transfected before 
treatment. At the desired time point, the number of viable 
cells was determined by adding 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS)-based CellTiter 96 AQueous One 
Solution Reagent (Promega) to each well and measuring 
the absorbance at 490 nm on a SPECTRA MAX 190 
plate reader (Molecular Devices). Results were expressed 
as percentage of optical density, assuming that the 
absorbance of control cells was 100%. 
Western blot analysis
Whole cell extracts were prepared using 
radioimmunoprecipitation assay buffer (Thermo 
Scientific) containing protease inhibitor cocktails (Roche). 
Antibodies against CYP1B1 (Abcam) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; Santa Cruz 
Biotechnology) were used to detect protein expression.
Colony formation assay
Cells were seeded at 1,000 cells/plate and treated 
with doxetacel. After 14 days incubation, the colony were 
fixed with glutaraldehyde (6.0% v/v), stained with crystal 
violet (0.5% w/v) and counted with a microscope.
Apoptosis assay 
Apoptosis was analyzed with an annexin 
V-fluorescein isothiocyanate (FITC)/7-amino-actinomycin 
D (7-AAD) staining system (BD Biosciences) and a Cell 
Lab Quanta™ SC MPL (Beckman Coulter). Cells were 
stained with annexin V-FITC only (early apoptotic) or 
both annexin V-FITC and 7-AAD (late apoptotic) were 
considered as the apoptotic cell fractions.
CYP1B1 enzymatic activity
CYP1B1 enzymatic activity was determined 
using a P450-Glo Assay kit (Promega) according to the 
manufacturer’s instructions. The enzymatic activity was 
normalized to the protein content.
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Transfection
For CYP1B1 overexpression, cells were transfected 
with pCMV6-ENTRY vector expressing human CYP1B1 
cDNA or empty pCMV6-ENTRY vector (OriGene 
Technologies) using Fugene HD Transfection Reagent 
(Roche Diagnostics) according to the manufacturer’s 
protocol. For CYP1B1 knockdown, cells were transfected 
with 10 nM CYP1B1 siRNAs or universal scrambled 
negative control (OriGene Technologies). For miR-200c 
inhibition, cells were transfected with 20 nM Anti-miR 
miRNA Inhibitor for has-miR-200c or Anti-miR miRNA 
Inhibitor Negative Control (Ambion). For miR-200c 
overexpression, cells were transfected with 50 nM Pre-
miR miRNA Precursor of has-miR-200c or Pre-miR 
miRNA Negative Control (Ambion). LipofectamineTM 
2000 Tansfection Reagent (Invitrogen) was used for the 
transfection of CYP1B1 siRNA, miRNA precursor and 
inhibitor as described by the manufacturer’s instructions. 
Cells treated with LipofectamineTM 2000 Transfection 
Reagent alone were included as a mock control for each 
experiment. 
Quantitative RT-PCR
Total RNA was extracted from microdissected 
formalin-fixed, paraffin-embedded (FFPE) tissues and 
cultured cells using miRNeasy Mini Kit or RNeasy Mini 
Kit (Qiagen) and was converted into cDNA by using 
TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems) or iScript™ cDNA Synthesis Kit (BIO-
RAD) according to the manufacturer’s instruction. To 
assess gene expression, cDNAs were amplified with the 
TaqMan® Gene Expression Assays and TaqMan® Fast 
Universal PCR Master Mix using the 7500 Fast Real-
Time PCR System. The target genes and their Assay ID 
were as follows: CYP1B1 (Hs0016383_m1), GAPDH 
(Hs03929097_g1), miR-200c (002300) and RNU48 
(001006). The relative level was calculated by the 
comparative Ct method (∆∆Ct) using the 7500 Fast System 
Sequence Detection Software (Applied Biosystems). 
RCC tissue samples
Tissue samples of radical nephrectomy were 
obtained from the patients enrolled in the San Francisco 
Veterans Affairs Medical Center (SFVAMC). Informed 
consent was obtained from all patients. All slides 
were reviewed by a board-certified pathologist for 
the identification of tumor foci and normal adjacent 
tissue. For microdissections, 10 µm-unstained sections 
were microdissected with an Autopix Laser Capture 
Microdissection System (Molecular Devices) using 4 µm 
sections stained with hematoxylin and eosin and marked 
tumor and normal adjacent areas as a template.
Reporter assay
CYP1B1 3’UTR luciferase reporter clone 
was obtained from Origene Technologies along 
with control construct (pMirTarget). For miR-200c 
complementary sequence (MCS) mutants, deletion 
mutagenesis was conducted by overlap extension 
PCR [44]. The primer sequences are as follows: F1, 
5’-AAAGAATTCACAAGCCAAGGAAACTTGCCA-3’; 
F2, 5’-CTGAATGAATTGGTAACCAGGCCATTT-3’; 
F3, 5’-AAAAATCATTTTAAAGGCATTAGAGTC-3’; 
R1, 5’-GGTTACCAATTCATTCAGTAGTTTGGT-3’; 
R2, 5’-GCCTTTAAAATGATTTTTTATATTCAA-3’; 
R3, 5’-AAAGCGGCCGCTTGGTAATGGTGTC 
CCAGTAT-3’. After transfection, luciferase activity was 
measured with a PerkinElmer 2030 Multilabel reader 
(PerkinElmer) using the Dual-Glo Luciferase Assay 
System (Promega). 
Immunohistochemistry
Immunostaining was performed on FFPE RCC 
sections using the VECTASTAIN ABC Kit (Vector 
Laboratories) according to the manufacturer’s instructions. 
After incubation with anti-CYP1B1 antibody (Abcam), 
ImmPACT DAB (Vector Laboratories) was added as 
chromogen followed by counterstaining with hematoxylin. 
Staining intensity of each tissue section was visually 
evaluated with an Olympus BX60 microscope equipped 
with Spot Advanced software (Diagnostic Instruments) 
and was ranked on an overall scale from 0 to 3; with 0 
indicating the absence of staining; 1, weak staining; 2, 
moderate staining; and 3, strong staining.
In situ hybridization
In situ hybridization (ISH) was performed on 
FFPE RCC sections using the digoxigenin (DIG)-labeled 
miRCURY Locked Nucleic Acid (LNA) microRNA 
Detection probes for miR-200c and U6 (Exiqon) following 
the manufacturer’s protocol. Hybridization was performed 
overnight at 57 °C and detected with horseradish 
peroxidase-conjugated anti-DIG antibody (Abcam). 
Abundance of target RNA was detected using ImmPACT 
DAB peroxidase substrate (Vector Laboratories). 
Statistical analysis 
Values are presented as the mean ± standard error 
of mean (SEM) based on results obtained from at least 
three independent experiments. All statistical analyses 
were carried out using GraphPad PRISM Software. Two-
Oncotarget7786www.impactjournals.com/oncotarget
tailed unpaired Student’s t-test was used for comparisons 
between two groups. Chi-square test was used for 
analyzing the correlation between clinicopathologic 
parameters and CYP1B1 protein expression. Significance 
of percent survival after surgery was done with log-
rank test. The difference of miR-200c expression was 
determined by Mann-Whitney U test. The relationship 
between the levels of CYP1B1 protein and miR-200c was 
investigated by ANOVA and Tukey method test. A P value 
of <0.05 was regarded as statistically significant.
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